Monoamine oxidase inhibitors and their pharmacological significance.
The role of deprenyl, a selective monoamine oxidase B inhibitor, in the treatment of Parkinson's disease has been evaluated with special reference to the multiple pharmacological actions of the monoamine oxidase-inhibitory group of drugs.
D000818:Animals; D000928:Antidepressive Agents / Q000627:therapeutic use; D001921:Brain / Q000378:metabolism; D003010:Clorgyline / Q000627:therapeutic use; D006801:Humans; D008995:Monoamine Oxidase / Q000378:metabolism; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy*; D010627:Phenethylamines / Q000627:therapeutic use*; D051381:Rats; D012642:Selegiline / Q000627:therapeutic use*; D014439:Tyramine / Q000627:therapeutic use
D000928:Antidepressive Agents; D008996:Monoamine Oxidase Inhibitors; D010627:Phenethylamines; D012642:Selegiline; D008995:Monoamine Oxidase; D003010:Clorgyline; D014439:Tyramine